TECH · BIO-TECHNE Corp
$71.60
-0.17 (-0.24%)
At close · Jul 24
Market Cap
$11.21B
Shares
156.57M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$1.22B
+5.2%
FY2025
Net Income
$73.4M
-56.3%
FY2025
Gross Margin
64.8%
-1.6pp
FY2025
Operating Margin
8.38%
-9.4pp
FY2025
Diluted EPS
$0.46
-56.2%
FY2025
Operating Cash Flow
$287.56M
-3.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.21B | $1.22B | $1.16B | $1.14B | $1.11B | $931.03M | $738.69M | $714.01M | $642.99M | $563M | $499.02M | $452.25M | $357.76M | $310.58M | $314.56M | $289.96M | $269.05M | $263.96M | |
| $424.32M | $429.36M | $389.34M | $366.89M | $349.1M | $298.18M | $255.5M | $240.52M | $210.85M | $188.46M | $162.36M | $144.97M | $106.35M | $79.47M | $78.76M | $65.03M | $54.9M | $55.92M | |
| $786.49M | $790.27M | $769.73M | $769.82M | $756.5M | $632.85M | $483.19M | $473.49M | $432.14M | $374.54M | $336.66M | $307.28M | $251.41M | $231.11M | $235.8M | $224.94M | $214.15M | $208.03M | |
| — | 64.8% | 66.41% | 67.72% | 68.42% | 67.97% | 65.41% | 66.31% | 67.21% | 66.53% | 67.46% | 67.94% | 70.27% | 74.41% | 74.96% | 77.57% | 79.6% | 78.81% | |
| $96.85M | $99.5M | $96.66M | $92.49M | $87.14M | $70.6M | $65.19M | $62.41M | $55.33M | $53.51M | $45.19M | $40.85M | $30.95M | $29.26M | $27.91M | $25.99M | $25.12M | $23.56M | |
| $535.88M | $588.52M | $466.38M | $378.38M | $372.77M | $324.95M | $260.58M | $264.36M | $240.64M | $200.44M | $140.88M | $119.4M | $60.72M | $43.38M | $41.68M | $35.9M | $32.7M | $33.69M | |
| $64.54M | $76.04M | $79.85M | $77.49M | $74.15M | $64.94M | $61.1M | $58.72M | $47.08M | $44.39M | $29.4M | — | — | — | — | — | — | — | |
| — | $109.9M | $111.71M | $107.24M | $101.07M | $87.75M | $82.74M | $78.17M | $64.46M | $60.04M | $42.76M | $37.23M | $19.18M | $12.32M | $12.47M | $8.7M | $8.13M | $7.77M | |
| — | — | $12.25M | $3.83M | $1.64M | $142K | $87K | — | $376K | — | — | — | — | — | — | — | — | — | |
| $632.74M | $688.02M | $563.04M | $470.87M | $459.91M | $395.55M | $325.78M | $326.77M | $295.97M | $253.96M | $186.07M | $160.25M | $91.66M | $72.64M | $69.6M | $61.88M | $57.82M | $57.25M | |
| $153.76M | $102.26M | $206.69M | $298.94M | $296.59M | $237.3M | $157.42M | $146.72M | $136.18M | $120.58M | $150.59M | $147.02M | $159.75M | $158.47K | $166.21M | $163.06M | $156.33M | $150.78M | |
| — | 8.38% | 17.83% | 26.3% | 26.83% | 25.49% | 21.31% | 20.55% | 21.18% | 21.42% | 30.18% | 32.51% | 44.65% | 0.05% | 52.84% | 56.23% | 58.1% | 57.12% | |
| — | $212.16M | $318.4M | $406.18M | $397.66M | $325.04M | $240.16M | $224.89M | $200.64M | $180.62M | $193.36M | $184.25M | $178.93M | $12.48M | $178.68M | $171.76M | $164.46M | $158.55M | |
| $9.69M | $8.51M | $15.74M | $11.22M | $11.31M | $13.95M | $19.2M | $21.71M | $10.19M | $7.36M | $1.75M | $1.54M | $0 | $0 | — | — | — | — | |
| -$6.61M | -$3.79M | -$21M | $39.72M | $4.8M | -$89.12M | $119.06M | -$34.7M | -$10.23M | -$8.62M | -$3.11M | $7.14M | $1.64M | $2.19M | -$4.01M | $1.93M | $118K | $4.58M | |
| $772K | $938K | -$6.84M | -$1.14M | — | — | — | — | — | — | — | $0 | $0 | $570K | -$603K | -$926K | -$1.51M | -$1.29M | |
| — | — | $283K | $49.33M | $15.19M | -$68.05M | — | — | — | — | — | — | — | — | — | — | — | — | |
| $147.14M | $98.46M | $185.69M | $338.66M | $301.39M | $148.18M | $276.48M | $112.02M | $125.95M | $111.96M | $147.48M | $154.16M | $161.39M | $160.66M | $162.2M | $164.98M | $156.45M | — | |
| $37.58M | $25.06M | $17.58M | $53.22M | $38.29M | $8.59M | $47.18M | $15.94M | -$198K | $35.88M | $43.01M | $46.43M | $50.44M | $48.1M | $49.86M | $52.68M | $46.67M | $50.12M | |
| $109.56M | $73.4M | $168.11M | $285.26M | $272.05M | $140.41M | $229.3M | $96.07M | $126.15M | $76.09M | $104.48M | $107.74M | $110.95M | $112.56M | $112.33M | $112.3M | $109.78M | $105.24M | |
| — | 6.02% | 14.5% | 25.1% | 24.61% | 15.08% | 31.04% | 13.46% | 19.62% | 13.51% | 20.94% | 23.82% | 31.01% | 36.24% | 35.71% | 38.73% | 40.8% | 39.87% | |
| — | — | — | $179K | -$8.95M | -$825K | $0 | $0 | — | — | — | — | — | — | — | — | — | — | |
| $109.52M | $73.36M | $168.07M | $285.19M | $271.93M | $140.32M | $229.07M | $95.97M | $126.04M | $76.02M | $104.42M | — | — | — | — | — | — | — | |
| $124.76M | $91.84M | $155.85M | $294.4M | $254.14M | $180.32M | $215.62M | $82.05M | $130.27M | $97.56M | $64.66M | $82.53M | $91.01M | $105.34M | $150.4M | $117.25M | $96.02M | $85.64M | |
| USD/shares | — | $0.47 | $1.07 | $1.81 | $1.73 | $0.91 | $1.50 | $0.64 | $0.84 | $0.51 | $0.70 | $0.73 | $0.75 | $0.77 | $0.76 | $0.76 | $0.74 | $0.70 |
| USD/shares | — | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 | $1.46 | $0.62 | $0.83 | $0.51 | $0.70 | $0.72 | $0.75 | $0.76 | $0.76 | $0.76 | $0.74 | $0.70 |
| shares | — | 157.52M | 157.71M | 157.18M | 156.87M | 154.99M | 152.8M | 151.12M | 149.9M | 149.25M | 148.78M | 148.38M | 147.56M | 147.34M | 147.76M | 148.39M | 149.02M | 151.21M |
| shares | — | 159.72M | 160.77M | 161.86M | 164.11M | 161.93M | 157.6M | 155.57M | 152.22M | 150M | 149.3M | 148.92M | 148.02M | 147.6M | 148.02M | 148.69M | 149.39M | 151.6M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2025: $777.94M in buybacks, $774.33M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
103.77×
Biotechnology median 7.07×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Protein Sciences | $870,245,000 | $830,902,000 | $845,747,000 | $832,311,000 | $704,564,000 | $555,352,000 | $543,159,000 | $482,378,000 |
| Diagnostics and Spatial Biology | $346,263,000 | $326,392,000 | $292,602,000 | — | — | — | — | — |
| Diagnostics And Genomics | — | — | — | $274,843,000 | $227,744,000 | $184,549,000 | $171,674,000 | $161,151,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $683,230,000 | $657,747,000 | $642,465,000 | $614,107,000 | $502,080,000 | $404,407,000 | $391,191,000 | $346,293,000 |
| EMEA Excluding UK | $266,305,000 | $241,432,000 | $220,230,000 | $219,055,000 | $204,264,000 | $155,289,000 | $155,821,000 | $148,599,000 |
| China | $100,463,000 | $99,467,000 | $113,868,000 | $112,438,000 | $87,556,000 | $68,792,000 | $57,799,000 | $47,950,000 |
| APAC Excluding Greater China | $77,263,000 | $73,904,000 | $73,190,000 | $76,139,000 | $69,013,000 | $60,362,000 | $52,913,000 | $48,392,000 |
| United Kingdom | $54,827,000 | $50,012,000 | $49,457,000 | $48,637,000 | $40,945,000 | $30,411,000 | $34,975,000 | $33,704,000 |
| Rest of World | $37,547,000 | $36,498,000 | $37,492,000 | $35,223,000 | $27,174,000 | $19,430,000 | $21,307,000 | $18,055,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Consumables | $972,286,000 | $928,180,000 | $917,733,000 | $890,874,000 | $751,985,000 | $602,642,000 | $588,979,000 | $534,738,000 |
| Instruments | $112,086,000 | $108,270,000 | $112,085,000 | $120,758,000 | $93,782,000 | $71,462,000 | $67,538,000 | $61,784,000 |
| Service | $111,570,000 | $99,265,000 | $85,784,000 | $71,988,000 | $66,416,000 | $47,459,000 | $38,050,000 | $34,137,000 |
| Royalty | $23,693,000 | $23,345,000 | $21,100,000 | $21,979,000 | $18,849,000 | $17,128,000 | $19,439,000 | $12,334,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Protein Sciences | $370,353,000 | $354,775,000 | $373,684,000 | $377,623,000 | $330,225,000 | $234,929,000 | $240,919,000 | $209,880,000 |
| Diagnostics and Spatial Biology | $21,324,000 | $24,546,000 | $43,037,000 | — | — | — | — | — |
| Diagnostics And Genomics | — | $24,546,000 | $43,037,000 | $48,977,000 | $38,425,000 | $14,965,000 | $10,079,000 | $35,496,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Protein Sciences | 42.6% | 42.7% | 44.2% | 45.4% | 46.9% | 42.3% | 44.4% | 43.5% |
| Diagnostics and Spatial Biology | 6.2% | 7.5% | 14.7% | — | — | — | — | — |
| Diagnostics And Genomics | — | — | — | 17.8% | 16.9% | 8.1% | 5.9% | 22% |
Key facts
CIK
842023
CUSIP
09073M104
13F (30d)
118 filings
118 filers
Visit website
Investor relations